China unveils 15th Five-Year Plan for pharma industry, targeting revenue over 3.5 trillion yuan by 2030
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 18, China's Ministry of Industry and Information Technology (MIIT), the National Development and Reform Commission (NDRC), and eight other departments jointly released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets a target for above-scale pharmaceutical industrial enterprises to achieve operating revenue exceeding 3.5 trillion yuan by 2030. Key forward-looking indicators include an average annual growth rate of over 20% for the innovative drug sector, more than five products with global annual sales exceeding $1 billion, 50 pharmaceutical enterprises with annual revenues surpassing 10 billion yuan, and 20 pharmaceutical industrial parks at the hundred-billion-yuan level. For innovation-driven development, the plan targets an average annual R&D investment intensity of over 10% for listed pharmaceutical companies and a share of first-in-class new drugs accounting for more than 25% of the global total. The plan focuses on industrial scale and efficiency, innovation, enterprise cultivation, and cluster development.
Source report
Beijing, September 18 (Jin10 Data) — The Ministry of Industry and Information Technology (MIIT), the National Development and Reform Commission (NDRC), and eight other government departments jointly released the 15th Five-Year Plan for the Development of the Pharmaceutical Industry today.
Key Target for 2030
The plan proposes that by 2030, the operating revenue of above-scale pharmaceutical industrial enterprises will exceed 3.5 trillion yuan.
Forward-Looking Indicators
The plan outlines forward-looking indicators for the pharmaceutical industry during the 15th Five-Year Plan period, focusing on industrial scale and efficiency, innovation-driven development, enterprise cultivation, and cluster development. Key targets include:
- Steady improvement in industrial scale and efficiency
- Average annual growth rate of over 20% for the innovative drug sector
- More than five products with global annual sales exceeding $1 billion
- 50 pharmaceutical industrial enterprises with annual operating revenues surpassing 10 billion yuan
- 20 pharmaceutical industrial parks at the hundred-billion-yuan level
Innovation-Driven Development
Regarding innovation, the plan targets:
- An average annual R&D investment intensity of over 10% for listed pharmaceutical companies
- A share of first-in-class new drugs accounting for more than 25% of the global total
(Source: CCTV News)
Source
金十数据Eastern
Part of this Story
China issues 15th Five-Year Plan targeting 20% annual growth for innovative drugs by 2030